SkinBioTherapeutics – launch of first commercial product, high margin profit potential from this cracking share tip
By Tom Winnifrith and Steve Moore | Sunday 31 October 2021
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
SkinBioTherapeutics (SBTX) has announced it has commercially launched its probiotic food supplement to help alleviate the symptoms associated with psoriasis, AxisBiotix-Ps.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.